Drugs / CBT-006
last change Aug 2023 re-read 3 minutes ago

CBT-006

Developed for
eye adnexa disorder
Investigated by
Cloudbreak Therapeutics, LLC

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04884243 Sep 2021 → Aug 2023 eye adnexa disorder Cloudbreak Therapeutics, LLC Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CBT-006 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04884243 ↗
Route Topical “Study Treatment: CBT-006 topical ophthalmic solution” NCT04884243 ↗